Clinical trials: Carcinoma Colon
Ovarian Cancer, Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent…
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Trial name
- NCT00959647
- Testing
- Vismodegib, FOLFOX, FOLFIRI
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Renal Cell Carcinoma, Non-small Cell Lung Cancer
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing…
- Conditions
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05769959
- Testing
- RO7515629, tocilizumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Study of rSIFN-co in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Carcinoma, Hepatocellular
- Trial name
- rSIFN-01 (NCT02387307)
- Testing
- rSIFN-co
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Peritoneal Carcinoma, Colorectal Carcinoma
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
This is a phase 1/2a open label study to evaluate the dose, safety, tolerability and efficacy of an IP α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC) from colorectal carcinoma…
- Trial name
- NCT03732781
- Testing
- Radspherin
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 47 people
- Sponsor
- Oncoinvent Solutions AS
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to…
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer
- Trial name
- NCT03207867
- Testing
- NIR178, PDR001
- Where
- 21 sites in United States, Argentina and 13 more
- Volunteers
- 315 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022.
- Trial name
- NCT02817633
- Testing
- TSR-022, Nivolumab, TSR-042
- Where
- 89 sites in United States, South Korea and 1 more
- Volunteers
- 463 people
- Sponsor
- Tesaro, Inc.
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
This was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab.
- Trial name
- NCT02205398
- Testing
- INC280, cetuximab
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Colorectal Cancer
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Colorectal cancer (CRC) is one of the most common human malignant tumors. The incidence and mortality of colorectal cancer in our country are on the rise.
- Trial name
- NCT03491709
- Testing
- anti-EGFR monoclonal antibody, Cetuximab injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
- Trial name
- NCT07578571
- Testing
- IM-1617
- Where
- 4 sites in United States
- Volunteers
- 175 people
- Sponsor
- Immunome, Inc.
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Liver Metastases, Colorectal Cancer
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.
- Trial name
- MT201-204 (NCT00866944)
- Testing
- Adecatumumab, Adecatumumab and FOLFOX, FOLFOX 4
- Where
- 16 sites in France, Germany
- Volunteers
- 35 people
- Sponsor
- Amgen Research (Munich) GmbH
Colorectal Cancer
An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)
This observational multicenter study will evaluate the differences in progression-free survival defined in specific subgroups of participants with metastatic colorectal cancer receiving bevacizumab (Avastin).
- Trial name
- NCT01775644
- Testing
- Bevacizumab
- Volunteers
- 3,003 people
- Sponsor
- Hoffmann-La Roche